MTUM vs XBI
iShares MSCI USA Momentum Factor ETF vs SPDR S&P Biotech ETF
- • MTUM has the lower expense ratio at 0.15% vs 0.35% for XBI.
- • MTUM pays a higher dividend yield (0.65%).
Side-by-side metrics
| Metric | MTUM | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.15% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.65% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $17.75B | $10.92B |
YTD return | 7.29% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.31 | 1.01 |
P/E ratio | 25.88 | — |
Last price | $69.80 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
MTUM top holdings
| AMD | Advanced Micro Devices Inc | 5.76% |
| MU | Micron Technology Inc | 5.02% |
| JNJ | Johnson & Johnson | 3.70% |
| CSCO | Cisco Systems Inc | 3.60% |
| XOM | ExxonMobil Holdings Corp | 3.24% |
| INTC | Intel Corp | 2.90% |
| PANW | Palo Alto Networks Inc | 2.77% |
| AMAT | Applied Materials Inc | 2.63% |
| GOOGL | Alphabet Inc Class A | 2.41% |
| UNH | UnitedHealth Group Inc | 2.32% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About MTUM
MTUM (iShares MSCI USA Momentum Factor ETF) is US large-caps with momentum tilt. Managed by iShares, the fund carries $17.8B in assets under management, an expense ratio of 0.15%, a dividend yield of 0.65%. Its largest holding is Advanced Micro Devices Inc (AMD), which represents 5.8% of the portfolio. Real Estate is the fund's largest sector exposure at 2.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.